Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Katerina-Marina Pilala und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Methyltransferases, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hellenic Foundation for Research and Innovation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6‐methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis. The screening cohort of the study included 213 patients. The UROMOL ( n = 535) was analyzed as a validation cohort for non‐muscle‐invasive BlCa (NMIBC), while the TCGA‐BLCA ( n = 412) and Mariathasan et al. ( n = 348) cohorts were analyzed for muscle‐invasive BlCa (MIBC). Disease recurrence/progression and patients' mortality were assessed as clinical endpoints for NMIBC and MIBC, respectively. Internal validation of Cox regression models was conducted using bootstrap analysis, while the clinical utility for patient prognosis was evaluated through decision curve analysis. Reduced METTL3 expression was correlated with muscle‐invasive disease and tumors of advanced stage. Loss of METTL3 expression at diagnosis was strongly associated with higher risk of short‐term progression (HR = 2.903, 95% CI: 1.303–6.464, p = 0.006) to invasive stages in NMIBC and with worse survival of MIBC patients (HR = 1.908, 95% CI: 1.020–3.567, p = 0.042). Consistently, validation cohorts confirmed the poor treatment outcomes in patients exhibiting loss of METTL3 . Finally, METTL3 ‐fitted multivariate models improved risk stratification and offered superior clinical benefit for NMIBC and MIBC prognostication compared to clinically established disease markers. Overall, loss of METTL3 expression correlates with inferior treatment outcomes in BlCa, driving more accurate risk stratification and ameliorating patients' prognosis in BlCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Clinical Biochemistry - Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, "P. & A. Kyriakou" Children's Hospital, Athens, Greece.
- First Department of Urology, "Laiko" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- First Department of Propaedeutic Surgery, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Katerina-Marina Pilala, Maria-Alexandra Papadimitriou, Konstantina Panoutsopoulou, Margaritis Avgeris, Andreas Scorilas
Förderung
- Hellenic Foundation for Research and Innovation
Zitieren
APA
Pilala, K. M., Koroneou, S., Papadimitriou, M. A., Panoutsopoulou, K., Soureas, K., Giagkos, G. C., Levis, P., Linardoutsos, D., Stravodimos, K., Avgeris, M., & Scorilas, A. (2026). Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients. International Journal of Cancer. https://doi.org/10.1002/ijc.70147
Vancouver
Pilala KM, Koroneou S, Papadimitriou MA, Panoutsopoulou K, Soureas K, Giagkos GC, et al. Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients. International Journal of Cancer. 2026. doi:10.1002/ijc.70147
BibTeX
@article{Pilala2026,
author = {Pilala, Katerina-Marina and Koroneou, Stella and Papadimitriou, Maria-Alexandra and Panoutsopoulou, Konstantina and Soureas, Konstantinos and Giagkos, Georgios-Christos and Levis, Panagiotis and Linardoutsos, Dimitrios and Stravodimos, Konstantinos and Avgeris, Margaritis and Scorilas, Andreas},
title = {Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70147}
}
EUVIMED